Cinacalcet Hydrochloride and Eribulin Mesylate

• Generic Name: cinacalcet
• Dosage Forms: n.a.
• Other Brand Names: Sensipar

Treatment of secondary hyperparathyroidism associated with chronic renal disease in patients who are undergoing hemodialysis or peritoneal dialysis.

Safety and efficacy in patients who are not undergoing dialysis have not been established.

May be used alone or in conjunction with vitamin D analogs and/or phosphate binders.

Effects on clinical outcomes remain to be fully determined. The primary finding of the EVOLVE trial (a lack of effect on mortality or major cardiovascular events ) is controversial because of study limitations.

Management of hypercalcemia associated with parathyroid carcinoma; designated an orphan drug by FDA for this use.

Treatment of hypercalcemia associated with primary hyperparathyroidism in patients who would be candidates for parathyroidectomy based on serum calcium concentrations but who are unable to undergo the surgery; designated an orphan drug by FDA for this use.

• Generic Name: eribulin
• Dosage Forms: n.a.
• Other Brand Names: Halaven

Treatment of metastatic breast cancer in patients who have previously received at least 2 chemotherapeutic regimens, including an anthracycline and a taxane, in either the adjuvant or metastatic setting.

There is no generally accepted standard of care for management of advanced and heavily pretreated anthracycline- and taxane-refractory metastatic breast cancer. Some clinicians recommend individualizing therapy based on factors such as patient’s disease stage and tumor type, performance status, quality of life, preferences, treatment history (e.g., toxicity), underlying medical conditions, and expected benefits and risks of each option.